New research from the Netherlands shows that the switch from screen film mammography (SFM) to digital mammography (DM) in large, population-based breast cancer screening programs improves the detection of life-threatening cancer without significantly increasing detection of clinically insignificant disease.
New research shows that a 12-month treatment programme of Herceptin is still the best option for women with HER2-positive breast cancer, according to the Breast Cancer Aotearoa Coalition (BCAC).
The latest data from two large clinical trials investigating Herceptin (trastuzumab) was presented at the European Society of Medical Oncology (ESMO) in Vienna, Austria overnight.
The deeper researchers dive into the genetics of breast cancer, the more complicated their discoveries. And the latest, and deepest, dive is no exception.
More than 1,700 post-menopausal women who have been treated with hormonal therapy for more than four years are invited to take part in this clinical trial run by the Australia New Zealand Breast Cancer Trials Group (ANZBCTG).
The study examines whether being given the drug Letrozole a year or more after completing hormonal therapy can prevent or delay breast cancer from recurring in postmenopausal women.
